| 摘要: | 子宮內膜癌(Endometrial Cancer, EC)的發生率在2010年時已正式超越子宮頸癌，成為女性生殖器官癌症首位，根據WHO2020年的統計，約有417367人確診子宮內膜癌，且有97370人死亡。在台灣的發生率也逐年攀升，且有年輕化的趨勢，子宮內膜癌好發於50-59歲停經後的婦女，根據108年癌症登記的統計，子宮內膜癌發生率在所有癌症中排名女性第五位，死亡率排名於女性第十一位。子宮內膜癌屬於預後良好的癌症，第一期病人的五年存活率平均為九成，第二期為八成，第三期為六成，但是到了第四期只剩下兩成，因此早期診斷對子宮內膜癌預後有很大的幫助。
生物標記為用以顯示病患生理狀態或疾病發展的生物分子，經常被用來作為早期診斷、治療、監控疾病的重要工具。現今的蛋白體技術使得我們能偵測到疾病生發時產生的血漿蛋白改變，包含了蛋白質濃度改變與不正常的區域分布。液相層析串聯式質譜儀(LC-MS/MS)屬於蛋白體分析技術的一種，結合了液相層析的物理分離能力和質譜的質量分析能力。具有高特異性與高靈敏度的特點，並且可以在複雜樣本內對目標蛋白進行偵測以及定量分析。目前已有許多研究透過液相層析串聯式質譜儀搭配多重反應監測開發可供診斷癌症的生物標記。
因此本研究的目的為使用液相層析串聯式質譜儀搭配多重反應監測比較子宮內膜癌患者與健康控制組之血漿蛋白的改變，挑選可以作為子宮內膜癌生物標記之候選胜?，後續使用酵素連結免疫吸附法(ELISA)對候選胜?之蛋白質進行臨床效能驗證分析，以尋找可作為子宮內膜癌新早期診斷生物標記之蛋白質。
The incidence of endometrial cancer (Endometrial Cancer, EC) officially surpassed cervical cancer in 2010 and became the first female reproductive organ cancer. According to the statistics of WHO in 2020, about 417,367 people were diagnosed with endometrial cancer, and there were 97,370 deaths. The incidence of endometrial cancer in Taiwan is also increasing year by year, and there is a trend of young people. Endometrial cancer is more likely to occur in women aged 50-59 after menopause, and according to the 108-year cancer registry, the incidence of endometrial cancer ranks fifth among all cancers in women, and the mortality rate ranks eleventh in women. Endometrial cancer is a cancer with a good prognosis. The five-year survival rate of patients with stage I is 90% on average, 80% for stage II, 60% for stage III, but only 20% for stage IV. Therefore, early diagnosis is very helpful for the prognosis of endometrial cancer.
Biomarkers are biomolecules used to indicate the physiological state of a patient or the development of a disease, and are often used as important tools for early diagnosis, treatment, and monitoring of disease. Today's proteomic technologies allow us to detect changes in plasma proteins produced during disease onset, including changes in protein concentration and abnormal regional distribution. Liquid chromatography tandem mass spectrometry (LC-MS/MS) is a protein analysis technique that combines the physical separation capabilities of liquid chromatography with the mass analysis capabilities of mass spectrometry. It is characterized by high specificity and sensitivity, and can detect and quantify target proteins in complex samples. Many studies have been conducted to develop biomarkers for cancer diagnosis using liquid chromatography tandem mass spectrometry with multiple reaction monitoring.
Therefore, the purpose of this study is to use liquid chromatography tandem mass spectrometry with multiple reaction monitoring to compare the changes in plasma proteins in patients with endometrial cancer and healthy controls, and to select candidate peptides that can be used as biomarkers for endometrial cancer. Follow-up Enzyme-linked immunosorbent assay (ELISA) was used to conduct Clinical efficacy verification analysis of candidate peptide proteins to find proteins that can be used as new early diagnostic biomarkers for endometrial cancer. |
